August 17, 2017August 17, 2017
Cell Therapy for Type of Epidermolysis Bullosa Advancing in Phase 1 Trial, Fibrocell Announces

In a recent update on its drug development program, Fibrocell Science addressed the therapy, FCX-007, it is developing for people ... Read more
August 9, 2017August 9, 2017
Amicus Therapeutics Advances Development of Investigational Therapy SD-101 for EPB

Amicus Therapeutics, a company developing therapeutics for rare diseases, recently released an update of the company’s clinical trial testing ... Read more
July 27, 2017July 27, 2017
Epidermolysis Bullosa Simplex Patients Need Better Pain Management Strategies, Small Study Finds

Many adults and children with epidermolysis bullosa simplex (EBS-l) experience pain that can significantly impact their quality of life, ... Read more
July 21, 2017July 21, 2017
InMed and ATERA Partner to Test Cannabinoid Therapy Candidate INM-750 in Epidermolysis Bullosa

Cannabinoid therapy developer InMed and French tissue engineering company ATERA have teamed up to develop 3-D human skin models ... Read more
July 19, 2017July 19, 2017
FDA Recommends Abeona’s EB-101 Gene Therapy to Advance Toward Phase 3 Trial

The U.S. Food and Drug Administration (FDA) recently recommended Abeona Therapeutics accelerate the clinical development program of its gene therapy candidate ... Read more
July 18, 2017July 18, 2017
EMA Grants TXA127 Orphan Drug Status to Treat Epidermolysis Bullosa

The European Medicines Agency (EMA) recently granted Tarix Orphan’s lead investigational product TXA127 orphan drug status for the ... Read more
July 14, 2017July 14, 2017
Trial Evaluating Diacerein 1% Ointment as EBS Treatment Enrolls First Patient

The first patient has enrolled in a clinical trial evaluating both the efficacy and safety of diacerein 1% ointment (CCP-020) ... Read more
July 13, 2017July 13, 2017
FDA Grants Rare Pediatric Disease Designation to EB-101 as a Treatment for Blistering Skin Disorder

The U.S. Food and Drug Administration has granted a Rare Pediatric Disease Designation to EB-101, Abeona Therapeutics’ ... Read more

Cell Therapy for Type of Epidermolysis Bullosa Advancing in Phase 1 Trial, Fibrocell Announces

In a recent update on its drug development program, Fibrocell Science addressed the therapy, FCX-007, it is developing for people with recessive dystrophic epidermolysis bullosa (RDEB). Results from the Phase ... Read more

August 9, 2017August 9, 2017

Amicus Therapeutics Advances Development of Investigational Therapy SD-101 for EPB

Amicus Therapeutics, a company developing therapeutics for rare diseases, recently released an update of the company’s clinical trial testing SD-101 as a potential therapy for patients with epidermolysis bullosa. ... Read more

July 27, 2017July 27, 2017

Epidermolysis Bullosa Simplex Patients Need Better Pain Management Strategies, Small Study Finds

Many adults and children with epidermolysis bullosa simplex (EBS-l) experience pain that can significantly impact their quality of life, but they lack access to adequate pain-management options, a questionnaire-based ... Read more

July 21, 2017July 21, 2017

InMed and ATERA Partner to Test Cannabinoid Therapy Candidate INM-750 in Epidermolysis Bullosa

Cannabinoid therapy developer InMed and French tissue engineering company ATERA have teamed up to develop 3-D human skin models with tissue taken from epidermolysis bullosa (EB) patients. The models ... Read more

July 19, 2017July 19, 2017

FDA Recommends Abeona’s EB-101 Gene Therapy to Advance Toward Phase 3 Trial

The U.S. Food and Drug Administration (FDA) recently recommended Abeona Therapeutics accelerate the clinical development program of its gene therapy candidate EB-101 for the treatment of patients with recessive dystrophic epidermolysis ... Read more

July 18, 2017July 18, 2017

EMA Grants TXA127 Orphan Drug Status to Treat Epidermolysis Bullosa

The European Medicines Agency (EMA) recently granted Tarix Orphan’s lead investigational product TXA127 orphan drug status for the treatment of epidermolysis bullosa (EB). Orphan drug status is granted by regulatory ... Read more

July 14, 2017July 14, 2017

Trial Evaluating Diacerein 1% Ointment as EBS Treatment Enrolls First Patient

The first patient has enrolled in a clinical trial evaluating both the efficacy and safety of diacerein 1% ointment (CCP-020) in treating epidermolysis bullosa simplex (EBS), Castle Creek Pharmaceuticals recently announced. ... Read more

July 13, 2017July 13, 2017

FDA Grants Rare Pediatric Disease Designation to EB-101 as a Treatment for Blistering Skin Disorder

The U.S. Food and Drug Administration has granted a Rare Pediatric Disease Designation to EB-101, Abeona Therapeutics’ treatment for the inherited skin disease epidermolysis bullosa, or EB. Importantly, the designation also ... Read more